XFOR Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
8.8M
+225.2%
2.7M
+5.5%
2.6M
+45.5%
1.8M
-10.5%
2.0M
Cost of Revenue
1.6M
+170.4%
598.0K
+64.3%
364.0K
+3.7%
351.0K
+7.7%
326.0K
Gross Profit
7.2M
+240.7%
2.1M
-4.3%
2.2M
+55.9%
1.4M
-14.1%
1.6M
Operating Expenses
23.6M
+5.2%
22.4M
-13.5%
25.9M
-10.4%
28.9M
+3.7%
27.9M
R&D
15.1M
-2.4%
15.4M
-16.6%
18.5M
+6.8%
17.3M
-5.5%
18.4M
SG&A
8.5M
+22.0%
7.0M
-5.6%
7.4M
-36.3%
11.6M
+21.6%
9.5M
Operating Income
-16391000
+19.3%
-20306000
+14.3%
-23699000
+13.9%
-27509000
-4.9%
-26232000
EBITDA
-15394000
+23.3%
-20083000
+14.5%
-23476000
+14.0%
-27286000
-5.4%
-25877000
Net Income
-16157000
+20.2%
-20241000
+15.4%
-23925000
+19.8%
-29815000
-15.8%
-25741000
EPS (Basic)
$-0.13
+18.8%
$-0.16
+23.8%
$-0.21
+69.6%
$-0.69
+80.1%
$-3.47
EPS (Diluted)
$-0.13
+18.8%
$-0.16
+23.8%
$-0.21
+69.6%
$-0.69
+80.1%
$-3.47
Shares (Diluted)
126.3M
+0.0%
126.3M
+13.1%
111.6M
+157.9%
43.3M
+483.7%
7.4M
X4 Pharmaceuticals (XFOR) โ€” Financials